-
Mashup Score: 9
The prevalence of obesity in the United States has increased significantly in recent decades [1,2]. Obesity is a potent risk factor for the development of heart failure (HF) [3–5]. As the obesity epidemic spreads, it will be increasingly important to understand the hemodynamic effects of obesity in both acute and chronic HF states.
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1A New Norm for Early-Career Advanced Heart Failure Clinicians - 2 year(s) ago
The path to becoming an advanced heart failure and transplant cardiologist (AHFTC) is long and arduous. In the final year of postgraduate training, fellows are expected to acquire rapidly both inpatient and outpatient expertise in heart failure, pulmonary hypertension, mechanical circulatory support, and heart transplantation in addition to numerous other competencies that are now expected in the…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
@dranulala @HFSA @theravishah @MHBeasleyMD @PPirlamarla_MD @ACCinTouch @AHajduczok @CardioNerds @KevinShahMD @ersied727 @Richardkcheng2 👏🏾👏🏾👏🏾 And, thanks so much for the shoutout to our recent @JCardFail Early Career & Trainee Spotlight piece A New Norm for Early-Career Advanced Heart Failure Clinicians @Nikhil15 https://t.co/IH8tUGZZ68 https://t.co/1M9hhzLrGZ
-
-
Mashup Score: 0Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure - 2 year(s) ago
The prevalence of heart failure (HF) continues to steadily rise and now more than 64 million people globally carry the diagnosis.1 Together with a 5-year survival rate of ∼50% and high rates of hospitalization, there are few other conditions across medicine that have such an unfortunate combination of being exceedingly common, morbid, and deadly.2 Fortunately, for patients with HF with reduced…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
Time to Quadruple Guideline-Directed Medical Therapy: Performance measure for #heartfailure by @gcfmd “despite clinical trial evidence & Class I guideline recommendations, the implementation of GDMT in real-world clinical practice remains overall poor” https://t.co/t4nA5rkEYX
-
-
Mashup Score: 4Epidemiology, Pathophysiology, Diagnosis, and Therapy of Heart Failure With Preserved Ejection Fraction in Japan - 2 year(s) ago
Heart failure (HF) is a global health care problem that has high morbidity and mortality rates.1 At present, more than half of patients with HF have preserved ejection fraction (HFpEF), and its prevalence relative to HF with reduced EF (HFrEF) is increasing due to the aging population and increasing burden of lifestyle-related comorbidities, such as systemic hypertension, diabetes, chronic kidney…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
RT @EchoLab_Gunma: われわれのReviewはこちら https://t.co/S3B0WVgxHo
-
-
Mashup Score: 4Multidisciplinary Care in Heart Failure Services - 2 year(s) ago
The burden of heart failure (HF) continues to increase over time, thereby creating a significant social and economic burden on the healthcare system1. Over the past decade, HF management has become exceedingly complex. With the advent of newer pharmacotherapeutics, devices, and interventions, morbidity and mortality have significantly improved2. It is often the case that patients with multiple…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
RT @KazuhikoKido: Please check out our manuscript: Multidisciplinary Care in Heart Failure Services https://t.co/wy3UkJKHDa. @docsok99 @MG…
-
-
Mashup Score: 28Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure - 2 year(s) ago
The prevalence of heart failure (HF) continues to steadily rise and now more than 64 million people globally carry the diagnosis.1 Together with a 5-year survival rate of ∼50% and high rates of hospitalization, there are few other conditions across medicine that have such an unfortunate combination of being exceedingly common, morbid, and deadly.2 Fortunately, for patients with HF with reduced…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
Don't delay. Fight clinical inertia. Start 4 pillars in eligible patients. Quickly. Time to consider the "time to #quadtherapy" performance measure for #HFrEF @IzzaShahid_ @gcfmd @DCRINews @JCardFail @JavedButler1 @robmentz @dranulala @AndrewJSauer https://t.co/uMWKc22Nw2 https://t.co/YI8uDx5P5l
-
-
Mashup Score: 16Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure - 2 year(s) ago
The prevalence of heart failure (HF) continues to steadily rise and now more than 64 million people globally carry the diagnosis.1 Together with a 5-year survival rate of ∼50% and high rates of hospitalization, there are few other conditions across medicine that have such an unfortunate combination of being exceedingly common, morbid, and deadly.2 Fortunately, for patients with HF with reduced…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
The time is right for consideration of “time to quadruple medical therapy” as an evidence-based performance measure for HF Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure https://t.co/6tqH7RePnE @SJGreene_md @JCardFail @HFSA
-
-
Mashup Score: 1Missense Genetic Variation of ICAM1 and Incident Heart Failure - 2 year(s) ago
Immune dysregulation may play a central role in the pathogenesis of certain heart failure (HF) syndromes, but precise mechanisms remain unclear (1,2). Specifically, chronic systemic inflammation driven by comorbidities may upregulate cellular adhesion molecules (CAMs) on the surface of endothelial cells, allowing for leukocyte infiltration of various tissue beds (1). This inflammatory cascade may…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
Future @IUCardsFellows fellow and current @NMCardioVasc research fellow Pedro Giro presents at #ACC23: A missense variant in ICAM1 that is common in Black individuals but rare in other race/ethnicities -> ⬆️HFpEF risk #ACC23 Sim Pub in @JCardFail: https://t.co/qvNNP2TXqe https://t.co/9Y86xLG11e
-
-
Mashup Score: 5Time to triple therapy in patients with de novo heart failure with reduced ejection fraction: a population-based study - 2 year(s) ago
Heart failure (HF) is a major public health problem, with frequent emergency department (ED) visits, hospital admissions and a 5-year survival rate of approximately 50% [1]. With the advent of novel therapies such as angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose co-transporter 2 inhibitors (SGLT2i), quadruple therapy is now recommended by practice guidelines in treating…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
Analysis of time to 💊💊💊 Rx is a very nice start The time to compressive 💊💊💊💊 GDMT is key to optimal HFrEF outcomes Time to triple therapy in patients with de novo heart failure with reduced EF: a population-based study https://t.co/FgpC7vLdeR? @SJGreene_md @JCardFail
-
-
Mashup Score: 9Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure - 2 year(s) ago
Soluble urokinase-type plasminogen activator receptor (suPAR) is a marker of immune activation and pathogenic factor for kidney disease shown to predict cardiovascular outcomes including heart failure (HF) in various populations. We characterized suPAR levels in patients with HF and compared its ability to discriminate risk to that of B-type natriuretic peptide (BNP).
Source: Journal of Cardiac FailureCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Never heard of suPAR? Check this article out now at JCF by @salimhayek et al Accompanying editorial @SarahHale321 & @NMHheartdoc @NorthwesternMed "Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure" https://t.co/39TF1RocwJ 🧵 https://t.co/e4K1cjPZd3
-
Congratulations to colleagues @CarsonKeckMD, @FudimMarat, @LitwinSheldon and #BarryBorlaug for completing this intriguing look at differing hemodynamic patterns between obese and non-obese patients during treatment for ADHF. https://t.co/h8piXYqzQS Summary figure: https://t.co/9Krp3Lb4tw